Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer

NCT01631552 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01631552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01631552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Completed
Start date
December 17, 2012
Completion date
August 13, 2020
Enrollment
515 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma breast stage iv, cervical cancer, endometrial cancer, esophageal cancer, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous cell, hepatocellular carcinoma, hormone-refractory prostate cancer, non-small cell lung cancer, ovarian epithelial cancer, pancreatic cancer, renal cell cancer, small cell lung cancer, triple negative breast cancer, urinary bladder neoplasms